Hematopoietic stem cells explained: the blood family tree and how a stem cell transplant works

Hematopoietic stem cells, usually shortened to HSCs or blood stem cells, are the cells that make all of your blood. The name is Greek in two halves: "hemato" for blood and "poiesis" for making. They are the best understood adult stem cells in the body and the only kind used in routine, approved treatment on a large scale, through what most people call a stem cell transplant or bone marrow transplant.
This guide covers what they are, the family tree of cells they produce, where transplant cells come from, the vocabulary patients hear along the way, and the myths that cause the most confusion.
What makes a blood stem cell a stem cell
Two abilities define an HSC. It can divide to make more HSCs (self-renewal), and it can produce every type of blood cell (multipotency). A cell that can do only one of those is not a stem cell in the strict sense.
The proof came from Toronto. In work published in 1961, James Till and Ernest McCulloch injected bone marrow cells into mice whose own marrow had been destroyed by radiation and saw small lumps form on the spleen, in proportion to the number of cells injected. Each lump turned out to be a colony grown from a single cell, and it contained several kinds of blood cell. Later experiments showed that those founding cells could also renew themselves. That was the first functional measurement of a stem cell.
HSCs are rare, a tiny minority of the cells in marrow, and most of them spend most of their time resting rather than dividing. Resting protects them from damage. The heavy lifting of daily blood production is done by their faster dividing descendants.
The blood family tree
Picture a tree with one trunk and two main branches.
The trunk is the HSC. Just below it sit multipotent progenitors, cells that can still make many blood types but can no longer renew themselves for long.
The myeloid branch produces:
- red blood cells, which carry oxygen and live about 120 days
- platelets, fragments of large cells called megakaryocytes, which help blood clot and last about a week to ten days
- neutrophils, the most common white cells, short-lived first responders to bacterial infection
- monocytes, which become macrophages in tissues
- eosinophils and basophils, involved in allergy and in fighting parasites
The lymphoid branch produces:
- B cells, which make antibodies
- T cells, which finish maturing in the thymus and coordinate or carry out immune attacks
- natural killer cells, which destroy infected and some cancerous cells
Because so many of these cells are short-lived, the marrow has to make billions of new ones every day for life. That is also why a working HSC graft rebuilds both the blood and the immune system. Our explainer on what immunology is goes further into the immune side of the tree.
Where they live, and how doctors collect them
In adults, HSCs live mainly in the marrow of flat bones such as the pelvis, breastbone and skull, and in the ends of long bones. They sit in specialized neighborhoods called niches, close to small blood vessels and to support cells that send signals telling them when to rest and when to divide.
Clinical labs count them, roughly, using a surface protein called CD34. A count of CD34-positive cells is the standard measure of how many stem and progenitor cells a collection holds. For an autologous transplant (the patient's own cells), centers commonly aim to collect at least about 2 million CD34-positive cells per kilogram of the patient's body weight.
Transplant cells come from three sources:
| Source | How it is collected | What to know |
|---|---|---|
| Mobilized peripheral blood | A growth factor drug pushes stem cells out of the marrow into the bloodstream over several days, then an apheresis machine filters them out of the donor's blood | The most common source for adults today; blood counts usually recover fastest |
| Bone marrow | Liquid marrow is drawn from the back of the pelvic bones under anesthesia | Still preferred in some situations, including many children's transplants |
| Umbilical cord blood | Collected from the placenta and cord after birth, then frozen in a public or private bank | Needs a less exact match, but holds fewer cells, so recovery is slower; the FDA approved an expanded cord blood product, Omisirge, in 2023 |
Our guide to cord blood banking explains the public and private models, and what blood stem cell donors go through describes donation from the donor's side.
Why transplant blood stem cells at all
There are two quite different reasons, and they correspond to the two main kinds of transplant.
| Autologous (your own cells) | Allogeneic (a donor's cells) | |
|---|---|---|
| Main purpose | Rescue the marrow after very high-dose chemotherapy | Replace a diseased blood or immune system with a healthy one |
| Typical uses | Multiple myeloma, some lymphomas | Leukemias, myelodysplastic syndromes, severe aplastic anemia, sickle cell disease, thalassemia, inherited immune deficiencies |
| Matching needed | None | HLA matching between donor and patient |
| Graft versus host disease | Not a risk | A major risk |
| Donor immune attack on cancer | No | Yes, the "graft versus leukemia" effect, one reason allogeneic transplants can cure some blood cancers |
The first successful allogeneic marrow transplants were reported in 1968, in children with inherited immune deficiencies. E. Donnall Thomas, who developed marrow transplantation for leukemia in Seattle, shared the 1990 Nobel Prize in Physiology or Medicine for that work.
A transplant, in the words you will hear
Patients and families often say the vocabulary is the hardest part at first. These are the terms that come up most, in roughly the order they appear.
HLA typing
A blood or cheek swab test that reads the immune "tags" a donor and patient carry. The closer the match, the lower the risk of rejection and graft versus host disease.
Conditioning
Chemotherapy, sometimes with radiation, given in the days before the transplant. It makes room in the marrow and, in an allogeneic transplant, suppresses the patient's immune system so the graft is not rejected. "Myeloablative" conditioning is the most intense; "reduced intensity" regimens are gentler and opened transplantation to older and less fit patients.
Day 0
The day the cells are given. The infusion itself usually looks much like a blood transfusion through a central line. The cells find their own way to the marrow.
Engraftment
The point at which the new cells start producing blood, usually defined by the neutrophil count rising and staying up. It often comes 2 to 4 weeks after infusion, usually sooner with mobilized blood cells and later with cord blood. Until then, infection is the main danger.
Graft versus host disease (GVHD)
Donor immune cells attacking the patient's tissues, most often skin, gut and liver. Acute GVHD tends to appear in the first months; chronic GVHD can appear later and last longer. In December 2024 the FDA approved Ryoncil (remestemcel-L), a mesenchymal stromal cell product, for steroid-refractory acute GVHD in children.
Chimerism
The share of the patient's blood cells that come from the donor. Teams track it to see whether the graft has taken fully.
Immune recovery and revaccination
Counts can recover within weeks, but the immune system takes months, often a year or more, to rebuild. Many allogeneic transplant recipients are given their childhood vaccines again.
Gene therapies built on blood stem cells
A newer group of treatments uses the patient's own HSCs, modified outside the body and returned after conditioning chemotherapy. The FDA has approved several, all listed on its page of approved cellular and gene therapy products: Zynteglo for beta thalassemia and Skysona for cerebral adrenoleukodystrophy (both 2022), Casgevy and Lyfgenia for sickle cell disease (both December 2023, Casgevy being the first CRISPR-based therapy approved by the FDA), and Lenmeldy for metachromatic leukodystrophy (2024). They avoid the need for a donor, but not the conditioning, which carries real risks of its own.
Myth vs fact
"A stem cell transplant is the same thing clinics offer for knees and backs."
Fact: Approved HSC transplants are hospital procedures for serious blood and immune diseases, using carefully counted and tested cells. Injections of fat or marrow cells sold for joint pain, lung disease or anti-aging are a different thing, and the FDA has warned the public repeatedly about unapproved stem cell products. Our guide to unproven stem cell clinic warning signs explains what to look for.
"Blood stem cells can become heart or brain cells."
Fact: Early 2000s reports that HSCs could routinely turn into heart muscle, liver or nerve cells mostly did not hold up when other labs tried to repeat them. HSCs make blood and immune cells. That is a big enough job.
"Engraftment means it is over."
Fact: Engraftment is the first milestone, not the last. Infection risk, GVHD and immune rebuilding continue for months, which is why follow-up visits are frequent in the first year.
"My child's stored cord blood can treat any disease they get."
Fact: A child's own cord blood carries the same genes as the child, so it is generally not suitable for treating an inherited disease in that same child, and many leukemia transplants call for donor cells rather than the patient's own. Medical groups give different advice on private banking for exactly these reasons.
"Everyone has a sibling match."
Fact: Each full brother or sister has about a 1 in 4 chance of being an HLA match, because each parent passes on one of two sets of HLA genes. Most patients have no matched sibling, which is why national registries such as NMDP and public cord blood banks exist.
If you or a family member is facing a transplant decision, the transplant team is the right source for questions about your own case. The practical step that helps most early on is simple: ask the coordinator for a written calendar from conditioning through day 100, since nearly every term above maps onto a date on it.
This explainer is general information, not medical advice. Decisions about treatment, donation or trials belong with a clinician who knows your history.



